Quick Answer
Royalty Pharma plc reported Diluted EPS of $1.78 per share for fiscal year 2025.
Royalty Pharma plc Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $1.78 | -6.8% |
| 2024 | $1.91 | -24.5% |
| 2023 | $2.53 | +2430.0% |
| 2022 | $0.10 | -93.3% |
| 2021 | $1.49 | +12.9% |
| 2020 | $1.32 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.67 | -44.6% | +857.1% |
| June 30, 2025 | $0.07 | -69.6% | -87.3% |
| March 31, 2025 | $0.55 | +5400.0% | -54.5% |
| September 30, 2024 | $1.21 | +656.2% | +426.1% |
| June 30, 2024 | $0.23 | -54.0% | +2200.0% |
| March 31, 2024 | $0.01 | -98.7% | -93.8% |
| September 30, 2023 | $0.16 | -50.0% | -68.0% |
| June 30, 2023 | $0.50 | -28.6% | -34.2% |
- Royalty Pharma plc showed a decrease of -6.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Royalty Pharma plc’s diluted eps has grown by 34.8% (from $1.32 per share to $1.78 per share).
- The most recent figure is from Royalty Pharma plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: